Ensysce Biosciences (ENSC) Common Equity (2017 - 2025)
Ensysce Biosciences (ENSC) posted quarterly Common Equity of $2.9 million for Q4 2025, down 14.65% year-over-year from $3.4 million in Q4 2024, and up 229.79% quarter-over-quarter from $874714.0 in Q3 2025.
Ensysce Biosciences (ENSC) Common Equity (2017 - 2025) Analysis & Trends
Ensysce Biosciences (ENSC) has reported Common Equity for 9 consecutive years, with $2.9 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Common Equity fell 14.65% year-over-year to $2.9 million; the TTM figure through Dec 2025 stood at $2.9 million (down 14.65% YoY), while the FY2025 annual figure was $2.9 million, down 14.65% from the prior year.
- Common Equity rose to $2.9 million in Q4 2025 per ENSC's latest filing, from $874714.0 in the prior quarter.
- Across five years, Common Equity topped out at $6.6 million in Q3 2024 and bottomed at -$8.2 million in Q4 2021.
- Historically, Common Equity has averaged $386474.3 across 5 years, with a median of $1.1 million in 2022.
- Annual changes were most pronounced in 2022 — Common Equity plunged 1566.79% — and 2024, when it soared 2344.15%.
- Ensysce Biosciences' Common Equity stood at -$8.2 million in 2021, then surged by 50.61% to -$4.0 million in 2022, then jumped by 83.84% to -$651267.0 in 2023, then jumped by 618.98% to $3.4 million in 2024, then dropped by 14.65% to $2.9 million in 2025.
- Business Quant data shows ENSC's Common Equity at $2.9 million in Q4 2025, $874714.0 in Q3 2025, and $3.1 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.29 Bn | 131.44 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 86.31 Bn | 78.32 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 65.22 Bn | 60.03 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.92 Bn | 53.78 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 42.07 Bn | 36.97 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 31.70 Bn | 28.39 Bn | 992.69 Mn | 1.35 Bn |
| 7 | BioNTech SE | 27.99 Bn | 9.60 Bn | 668.28 Mn | 22.38 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 757.49 Mn |
| 9 | Royalty Pharma | 27.28 Bn | 26.45 Bn | - | 9.79 Bn |
| 10 | Ensysce Biosciences | 930,885.21 | -3.38 Mn | - | 3.21 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.88 Mn |
| Sep 30, 2025 | 874,714.00 |
| Jun 30, 2025 | 3.06 Mn |
| Mar 31, 2025 | 2.72 Mn |
| Dec 31, 2024 | 3.38 Mn |
| Sep 30, 2024 | 6.58 Mn |
| Jun 30, 2024 | 1.48 Mn |
| Mar 31, 2024 | 3.42 Mn |
| Dec 31, 2023 | -651,267.00 |
| Sep 30, 2023 | 1.16 Mn |
| Jun 30, 2023 | 3.79 Mn |
| Mar 31, 2023 | -152,424.00 |
| Dec 31, 2022 | -4.03 Mn |
| Sep 30, 2022 | -6.42 Mn |
| Jun 30, 2022 | -797,578.00 |
| Mar 31, 2022 | 1.11 Mn |
| Dec 31, 2021 | -8.16 Mn |
| Sep 30, 2021 | -385,287.00 |
| Jun 30, 2021 | 5.17 Mn |
| Mar 31, 2021 | -7.30 Mn |